Table 3. Clinical and histopathological informations in 34 gliomas analyzed.
| ID | Age | M/F | Pathology | Treatment |
|---|---|---|---|---|
| GBM.1 | 72 | H | GBM | STUPP |
| GBM.2 | 77 | H | GBM | BCNU+TMZ |
| GBM.3 | 81 | H | GBM | STUPP |
| GBM.4 | 58 | H | GBM | STUPP |
| GBM.5 | 59 | H | GBM | STUPP |
| GBM.6 | 65 | H | GBM | STUPP |
| GBM.7 | 58 | H | GBM | STUPP |
| GBM.8 | 76 | F | GBM | BCNU+TMZ |
| GBM.9 | 42 | F | GBM | STUPP |
| GBM.10 | 69 | H | GBM | STUPP |
| GBM.11 | 65 | H | GBM | STUPP |
| GBM.12 | 56 | H | GBM | STUPP |
| GBM.13 | 53 | H | GBM | STUPP |
| GBM.14 | 69 | H | GBM | STUPP |
| GBM.15 | 68 | H | GBM | STUPP |
| GBM.16 | 50 | F | GBM | STUPP |
| GBM.17 | 80 | H | GBM | BCNU+TMZ |
| GBM.18 | 65 | H | GBM | STUPP |
| GBM.19 | 58 | H | GBM | STUPP |
| GBM.20 | 59 | H | GBM | STUPP |
| GBM.21 | 58 | H | GBM | STUPP |
| GBM.22 | 42 | F | GBM | STUPP |
| GBM.23 | 65 | H | GBM | STUPP |
| GBM.24 | 69 | H | GBM | STUPP |
| ODG.25 | 27 | H | oligodendroglioma | - |
| AO.26 | 53 | F | anaplastic oligodendroglioma | TMZ |
| AA.27 | F | anaplastic astrocytoma | - | |
| OA.28 | 45 | H | oligoastrocytoma | - |
| OA.29 | 49 | F | oligoastrocytoma | TMZ |
| AA.30 | 43 | H | anaplastic astrocytoma | RT |
| AA.31 | 64 | H | anaplastic astrocytoma | VCR+RT |
| ODG.32 | 52 | H | oligodendroglioma | RT |
| ODG.33 | 40 | H | oligodendroglioma | - |
| ODG.34 | 41 | H | oligodendroglioma | RT |
RT, radiation therapy; TMZ, temozolomide; BCNU, bis-chloroethylnitrosourea; VCR, vincristine; STUPP, radiotherapy plus concomitant and adjuvant temozolomide.